Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) (Q63062406)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) |
clinical trial |
Statements
Open-Label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML) (English)
0 references
July 2004
0 references
December 2007
0 references
130
0 references
18 year
0 references